Paste your HTML here
We follow the science and put patients first
We are a global, science-led, patient-focused pharmaceutical business. We are committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life.
Our Annual Report is intended for shareholders, investor audiences and financial/business media only.
Our Annual Report is intended for shareholders, investor audiences and financial/business media only.
We have more than 100 Phase III studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.
Michel Demaré, Chair, AstraZeneca
Use a maximum of two downloads here
In addition to delivering medicines today, we are following the science to deliver medicines for tomorrow and the day after.
Pascal Soriot, Chief Executive Officer, AstraZeneca
Use a maximum of two downloads here
Our performance
In 2025, we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase III studies during the year and now have 16 blockbuster medicines.
Total Revenue
$58.7bn •
Up 9% at actual rate of exchange to $58,739 million
(up 8% at CER)
Reported EPS
$6.60
Up 45% at actual rate of exchange to $6.60
(up 43% at CER)
Core EPS
$9.16 •
Up 12% at actual rate of exchange to $9.16
(up 11% at CER)
Dividend
$3.20
Up 3%
• Used for remuneration of Executive Directors
Strategic overview
Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society, the planet and our shareholders.
Ambition 2030
Our ambition is to be pioneers in science, lead in our disease areas, and transform patient outcomes. By 2030, we aim to launch at least 20 new medicines and achieve $80 billion in Total Revenue with sustained growth thereafter.
Science and Innovation
Advances in science and technology are revolutionising the way we work, enabling us to push the boundaries to deliver new and better medicines and treatments more quickly to more patients.
Our strategic focus areas:
- Deliver the next wave of pipeline innovation
- Accelerate platform of therapeutic modalities
- Transform R&D ways of working
2025 achievements:
38
Pipeline progression events
97
Regulatory events •
• Used for remuneration of Executive Directors
Growth and Therapy Area Leadership
We are working across our therapy areas to transform care and meet the increasing demand for healthcare by improving access to our medicines, expanding treatment options and enabling patients to take control of their own health.
Our strategic focus areas:
- Deliver industry-leading growth in our therapy areas
- Improve patient outcomes by transforming care
- Realise world-class supply chains
2025 achievements:
$58.7bn
Total Revenue
9%
Actual growth (8% at CER)
People and Sustainability
Recognising the interconnection between business growth and societal needs, our sustainability strategy is focused on action on climate and nature, health equity and health systems resilience. We cultivate an inclusive, diverse workplace where employees thrive and are empowered to make an impact for people, society and the planet.
Our strategic focus areas:
- Deliver a great employee experience
- Lead on climate, equity and resilience
- Enable an agile organisation
2025 achievements:
86%
Employee belief that AstraZeneca is a great place to work
88.1%
Reduction in Scope 1 and 2 greenhouse gas emissions since 2015
Therapy areas
We are focused on therapy areas where we can transform patient outcomes through novel medicines and combinations. We deliver a diversified portfolio of medicines across primary care, specialty care and rare diseases through our broad-based global network.
Oncology
We are leading a revolution to transform cancer care. Our ambition is to eliminate cancer as a cause of death. We seek to transform outcomes for people living with cancer through innovative medicines, powerful combinations and a world-class, purpose-driven team.
BioPharmaceuticals
Our ambition is to transform care for billions of people living with chronic diseases and deliver long-lasting immunity.
We are working to intervene earlier to protect vital organs, slow or reverse disease progression, and achieve remission for often degenerative debilitating and life-threatening conditions, so many more people can live better, healthier lives.
Rare Disease
We continue to advance a diversified pipeline across disease areas with significant unmet medical need, where scientific progress has been absent or limited, advancing first- and/or best-in-class medicines and new modalities, while expanding our global geographic footprint for the rare disease community.
People
We rely on our global workforce to uphold our Code of Ethics and behaviours in line with our Values, to deliver our Ambition 2030 strategic priorities and work to sustain and improve short-and long-term performance.
Enabling an agile organisation
We are guided by our Values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance.
2025 achievement:
- 86% believe that AstraZeneca is a great place to work
Inclusion and diversity
Our global commitment to inclusion and diversity is woven into what we do, and is reflected in our Values and the behaviours that underpin them.
2025 achievement:
- 87% feel they can be themselves without worrying about being accepted
Skills and capabilities
We develop strategic capabilities through development programmes and high potential talent initiatives, supporting employees ranging from early talent and individual contributors to enterprise leaders.
2025 achievement:
- 81% feel they have the opportunity for personal development and growth
Sustainability
Recognising the strong connection between business growth and resilience, and the need to address the major health challenges of our time, we are focused on how we deliver sustainable impact and how we do business, underpinned by science.
Accessible and affordable healthcare
Our medicines impact more than 100 million patient lives annually, ranging from cancer and chronic diseases to rare diseases. We are closing healthcare gaps along the entire patient journey to improve access to screening, early detection, diagnosis and treatment, and innovating to deliver our life-changing medicines in a sustainable and equitable way.
2025 achievements:
320 million
people positively impacted since 2024, including:
156 million
from underserved groups
Climate change
In support of our Ambition 2030 strategy, we have set and are delivering action on our corporate climate targets. We are decarbonising our value chain including our own operations, and through global initiatives and collaboration with our peers, we are driving action to accelerate the delivery of net-zero healthcare.
2025 achievements:
88.1%
reduction of Scope 1 and Scope 2 GHG emissions from 2015 baseline year
Downloads
Annual Report Downloads
